Journal article · 2013 · Open access
Potential of patient-reported outcomes as nonprimary endpoints in clinical trials
Health and Quality of Life Outcomes, 11(1), 83 · Published 15 May 2013 · DOI 10.1186/1477-7525-11-83
In brief
“Potential of patient-reported outcomes as nonprimary endpoints in clinical trials” is a 2013 journal article by Ari Gnanasakthy and 4 co-authors, published in Health and Quality of Life Outcomes. OpenAlex counts 47 citations as of 22 November 2026. It is open access under a CC BY licence: the full text is free to read at Health and Quality of Life Outcomes.
- Citations
- 47
- Most cited in
- 2019 (17)
- Field-weighted impact
- 2.85
- References
- 19
- Authors
- 5
Abstract
BACKGROUND: The purpose of this research was to fully explore the impact of endpoint type (primary vs. nonprimary) on decisions related to patient-reported outcome (PRO) labeling claims supported by PRO measures and to determine if nonprimary PRO endpoints are being fully optimized.This review examines the use of PROs as both primary and nonprimary endpoints in support of demonstration of treatment benefit of new molecular entities (NMEs) and biologic license applications (BLAs) in the United States in the years 2000 to 2012. METHODS: All NMEs and BLAs approved by the Food and Drug Administration (FDA) between January 2000 and June 2012 were identified using the FDA Drug Approval Reports Web page. Generic products granted tentative approvals were excluded. For all identified products, medical review sections from publicly available drug approval packages were reviewed to identify PRO endpoint status. Product labels (indication, clinical trials sections) were reviewed to determine the number and type of PRO claim. RESULTS: A total of 308 NMEs/BLAs were identified. Of these, 70 NMEs/BLAs (23%) were granted PRO claims. The majority of product claims were for disease- or condition-specific signs and symptoms. Of the 70 products with PRO claims, a PRO was a primary endpoint for the vast majority (57 [81%]). A total of 19 of the 70 products were granted a PRO claim based on a nonprimary endpoint. While nonprimary endpoints were used most often to support claims of improved signs or symptoms, nonprimary endpoints were much more likely to support claims of higher order impacts. CONCLUSIONS: Successful PRO labeling claims are typically based on primary endpoints assessing signs and symptoms. Based on this research, studies with PROs as primary endpoints are far more likely to facilitate positive regulatory review and acceptance of PROs in support of labeling claims. Although inclusion of PROs as nonprimary endpoints in clinical trials has its challenges, recent PRO labels granted by the FDA show that they can indeed be candidates for PRO labeling claims as long as they are supported by evidence.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Gnanasakthy, A., Lewis, S., Clark, M., Mordin, M., & DeMuro, C. (2013). Potential of patient-reported outcomes as nonprimary endpoints in clinical trials. Health and Quality of Life Outcomes, 11(1), 83. https://doi.org/10.1186/1477-7525-11-83
MLA 9
Gnanasakthy, Ari, et al. “Potential of patient-reported outcomes as nonprimary endpoints in clinical trials.” Health and Quality of Life Outcomes, vol. 11, no. 1, 2013, p. 83. https://doi.org/10.1186/1477-7525-11-83.
Chicago
Gnanasakthy, Ari, Sandra Lewis, Marci Clark, Margaret Mordin, and Carla DeMuro. 2013. “Potential of patient-reported outcomes as nonprimary endpoints in clinical trials.” Health and Quality of Life Outcomes 11 (1): 83. https://doi.org/10.1186/1477-7525-11-83.
Harvard
Gnanasakthy, A. et al. (2013) ‘Potential of patient-reported outcomes as nonprimary endpoints in clinical trials’, Health and Quality of Life Outcomes, 11(1), p. 83. doi:10.1186/1477-7525-11-83.
IEEE
A. Gnanasakthy, S. Lewis, M. Clark, M. Mordin, and C. DeMuro, “Potential of patient-reported outcomes as nonprimary endpoints in clinical trials,” Health and Quality of Life Outcomes, vol. 11, no. 1, p. 83, 2013, doi: 10.1186/1477-7525-11-83.
BibTeX
@article{gnanasakthy2013potential,
title = {{Potential of patient-reported outcomes as nonprimary endpoints in clinical trials}},
author = {Gnanasakthy, Ari and Lewis, Sandra and Clark, Marci and Mordin, Margaret and DeMuro, Carla},
journal = {Health and Quality of Life Outcomes},
year = {2013},
volume = {11},
number = {1},
pages = {83},
doi = {10.1186/1477-7525-11-83},
url = {https://doi.org/10.1186/1477-7525-11-83}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2016 | 3 | |
| 2017 | 3 | |
| 2018 | 4 | |
| 2019 | 17 | |
| 2020 | 2 | |
| 2021 | 1 | |
| 2022 | 1 | |
| 2023 | 1 | |
| 2024 | 4 | |
| 2026 | 1 |
Its field-weighted citation impact is 2.85: it has been cited 2.85 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- patient-reported outcomes
- primary endpoint
- new chemical entities
- Biologics License Application
- FDA drug approval
- regulatory review
- signs and symptoms
- clinical trial endpoints
Work with this paper
Most-cited papers in Mathematics
- Random ForestsLeo Breiman · Machine Learning · 2001 · 142,830 citations
- Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple TestingYoav Benjamini, Yosef Hochberg · Journal of the Royal Statistical Society Series B (Statistical Methodology) · 1995 · 113,923 citations
- Fitting Linear Mixed-Effects Models Using lme4Douglas M. Bates, Martin Maechler, Benjamin M. Bolker and 1 more · Journal of Statistical Software · 2015 · 100,328 citations
- The moderator-mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations.Reuben M. Baron, David A. Kenny · Journal of Personality and Social Psychology · 1986 · 95,866 citations
- Using multivariate statisticsBarbara Gerson Tabachnick, Linda S. Fidell · 1983 · 79,867 citations
Questions about this paper
How do I cite this paper in APA style?
Gnanasakthy, A., Lewis, S., Clark, M., Mordin, M., & DeMuro, C. (2013). Potential of patient-reported outcomes as nonprimary endpoints in clinical trials. Health and Quality of Life Outcomes, 11(1), 83. https://doi.org/10.1186/1477-7525-11-83
How many times has this paper been cited?
47 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Health and Quality of Life Outcomes: sign in and open the PDF from this page.
Who wrote this paper?
Ari Gnanasakthy, Sandra Lewis, Marci Clark, Margaret Mordin, Carla DeMuro.
What is the DOI of this paper?
10.1186/1477-7525-11-83, permanently at https://doi.org/10.1186/1477-7525-11-83. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.